Imperial College London

DrMichaelDelves

Faculty of Natural SciencesDepartment of Life Sciences

Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 5422michael.delves00

 
 
//

Location

 

Baum Lab SAFSir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Summary

As manager of the Imperial-Medicines for Malaria Venture Centre of Excellence, my main research interest is to understand the complex cell biology of Plasmodium transmission stage development and use this knowledge to help discover new drugs to eradicate malaria.

Plasmodium transmission to the mosquito is mediated by the sexually dimorphic male and female gametocytes. In P. falciparum, gametocyte development takes ~10 days, and maturation is linked to loss of sensitivity to most antimalarials. This can cause the unfortunate situation in which a malarial patient can be cured of disease symptoms triggered by the asexual parasites, but are left with gametocytes that are still infectious to mosquitoes thus perpetuating the disease cycle. Eradication of malaria will require new therapies to prevent parasite transmission to the mosquito.

I have recently shown that male gametocytes are more drug-sensitive than female gametocytes and so optimum drug discovery should take advantage of this weakness. To this end I have developed high throughput assays to screen small molecule libraries against both male and female gametocytes simultaneously to identify new lead transmission-blocking molecules. Additionally, little is known about how the gametocyte prepares for onward transmission. My work also aims to better understand the fine balance between quiescence and explosive development in mature gametocytes.

Publications

Journals

Marques J, Valle-Delgado JJ, Urbán P, et al., 2017, Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery., Nanomedicine, Vol:13, Pages:515-525

Baragana B, Norcross NR, Wilson C, et al., 2016, Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy, Journal of Medicinal Chemistry, Vol:59, ISSN:0022-2623, Pages:9672-9685

Baragaña B, Hallyburton I, Lee MC, et al., 2016, Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis., Nature, Vol:537

Delves MJ, Straschil U, Ruecker A, et al., 2016, Routine in vitro culture of P. falciparum gametocytes to evaluate novel transmission-blocking interventions, Nature Protocols, Vol:11, ISSN:1754-2189, Pages:1668-1680

Le Bihan A, de Kanter R, Angulo-Barturen I, et al., 2016, Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling, Plos Medicine, Vol:13, ISSN:1549-1676

More Publications